{"id":793050,"date":"2024-12-06T08:04:18","date_gmt":"2024-12-06T13:04:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/"},"modified":"2024-12-06T08:04:18","modified_gmt":"2024-12-06T13:04:18","slug":"celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/","title":{"rendered":"Celularity Reports Over Sevenfold Growth in Net Product Sales\u00a0through Third Quarter 2024 Compared to Third Quarter 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <em>Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024,\u00a0<\/em><br \/>\n          <em>and is now current with its quarterly report filings<\/em>\n        <\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <em>Reported Total Net Revenue for the Three Months and the Nine Months ending September 30, 2024, are consistent with last guidance, with significant growth over the same periods in 2023<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">FLORHAM PARK, N.J., Dec.  06, 2024  (GLOBE NEWSWIRE) &#8212; Celularity Inc. (Nasdaq: CELU) (\u201cCelularity\u201d or the \u201cCompany\u201d), a regenerative and cellular medicine company, today announced that it filed its <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oS2D06n1cLgYxzsdNil9bpSpYtAF8fFm-0RoW7IJiqoxiKFmFtOQ9VYBJXr-j7ibbnEixezuPiySCW8vUE8yoId-ZnA_clZnq5IqaBOT_BPweDJWRzyChrSxwXG4C6tSzGuO0zl5PrPyO6mpERAdmcOyZ3rKiFmroU0TifXkRi8=\" rel=\"nofollow\" target=\"_blank\">Quarterly Report on Form 10-Q<\/a> for the period ended September 30, 2024. With this filing, the Company is now current on its quarterly report filings.<\/p>\n<p align=\"justify\">For the nine months ended September 30, 2024, Celularity reported total net revenues of $36.1 million, an increase of $25.4 million, or 238.6%, compared to $10.7 million for the same period last year. For the three months ended September 30, 2024, total net revenues were $9.3 million, an increase of $5.5 million, or 145.5%, compared to $3.8 million for the same period last year. Product sales, net, which includes direct-to-customer sales of our advanced biomaterial products, saw the largest growth, reaching $26.2 million for the nine months ended September 30, 2024, compared to $3.6 million for the same period last year, or an increase of 621.1%.<\/p>\n<p align=\"justify\">\u201cOur reported revenue through September 30, 2024, confirms the confidence we have expressed throughout this year, including the recent announcement that we were raising the full-year net sales guidance we issued in February,\u201d said Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO. \u201cIn parallel with growing revenue, we continue to exercise discipline on the expense side and to evaluate opportunities to realign as the business evolves and grows, including in Asia Pacific with our strategic partner Genting Berhad as well as leveraging our cell therapy platform and technical operations capabilities.\u201d<\/p>\n<p align=\"justify\">On November 27, 2024, Celularity announced that it received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (\u201cNasdaq\u201d) stating that Celularity does not comply with the Nasdaq continued listing requirements due to the Company\u2019s inability to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the \u201cQ3 Form 10-Q\u201d). Celularity has now filed its Q3 Form 10-Q in compliance with the Nasdaq continued listing requirements.<\/p>\n<p align=\"justify\">Dr. Hariri added, \u201cWith the completion of our quarterly report on Form 10-Q for the third quarter 2024, we reaffirm our commitment to maintaining compliance with the Nasdaq listing requirements. As announced previously, we continue to strengthen our reporting processes by implementing several key improvements to help mitigate future delays and ensure timely and accurate financial disclosures.\u201d<\/p>\n<p>\n        <strong>About Celularity<\/strong>\n      <\/p>\n<p>Celularity Inc. (Nasdaq: CELU) is a regenerative medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity believes that by harnessing the placenta\u2019s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. For more information, visit www.celularity.com.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p>This release includes \u201cforward-looking statements\u201d within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are \u201cforward-looking statements,\u201d including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cforecast,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201coutlook,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include express or implied statements regarding expected net sales for the quarter ended September 30, 2024, growth relative to prior periods, its 2024 financial goals and expectations for future financial results, compliance with the Nasdaq listing rules, the sufficiency of the improvements to its reporting processes, and its ability to meet future reporting deadlines. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: Celularity\u2019s liquidity situation; the volatility in Celularity\u2019s stock price; inherent risks in biotechnological development, including with respect to the development of novel advanced biomaterials; and the regulatory approval process; along with those risk factors set forth under the caption \u201cRisk Factors\u201d in Celularity\u2019s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on July 30, 2024, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity\u2019s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity\u2019s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.<\/p>\n<p>\n        <strong>Investor Contact<\/strong>:<br \/>Carlos Ramirez<br \/>Senior Vice President, Celularity Inc.<br \/>Carlos.ramirez@celularity.com<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Raquel Cona \/ Michaela Fawcett<br \/>KCSA Strategic Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nyqR3NC6WgBBu449HgGsp0Mv4j1wYdhry9IUWs8LiQupF-H_NYXqK1avw3-WF6g4H80G7NgNUun3wlR7sOwizQ==\" rel=\"nofollow\" target=\"_blank\">rcona@kcsa.com<\/a> \/\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tdzsTLbVV48OAm_BpkfJKyZRUUF8IBjSENTQLtik9OaoJrVCbhTNRkim9N7Fw2GucX8UuxrAd79C3ebNC8OLVLAXTzHEdFCe8PKVZ_uK8l8Ao3g_feCsJsKpVBPoh66VwR5eyBPS2VH9v4_C7MgQM8NMSxUoGjE02ecbzdiDd_M51AEvCRyyP5_keSeFqlchxKd8Xfrjd3XSjjp3TIH6XMpHKgm1qyRh8RI2aXtiC5W8CL4iwywoLrzHuVjTs2z5Pzn-uzI3qiu6kkizan4m7Q==\" rel=\"nofollow\" target=\"_blank\">mfawcett@kcsa.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTQxOSM2NjI2NDM0IzIyMDUwMDk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTRjZTMyZGQtN2Y1Yi00MDVmLThlNGQtOTg5OTI2M2I2NmQ5LTEyMTY1NjI=\/tiny\/Celularity-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024,\u00a0 and is now current with its quarterly report filings Reported Total Net Revenue for the Three Months and the Nine Months ending September 30, 2024, are consistent with last guidance, with significant growth over the same periods in 2023 FLORHAM PARK, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) &#8212; Celularity Inc. (Nasdaq: CELU) (\u201cCelularity\u201d or the \u201cCompany\u201d), a regenerative and cellular medicine company, today announced that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. With this filing, the Company is now current on its quarterly report filings. For the nine months ended September 30, 2024, Celularity reported total net &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Celularity Reports Over Sevenfold Growth in Net Product Sales\u00a0through Third Quarter 2024 Compared to Third Quarter 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-793050","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celularity Reports Over Sevenfold Growth in Net Product Sales\u00a0through Third Quarter 2024 Compared to Third Quarter 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celularity Reports Over Sevenfold Growth in Net Product Sales\u00a0through Third Quarter 2024 Compared to Third Quarter 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024,\u00a0 and is now current with its quarterly report filings Reported Total Net Revenue for the Three Months and the Nine Months ending September 30, 2024, are consistent with last guidance, with significant growth over the same periods in 2023 FLORHAM PARK, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) &#8212; Celularity Inc. (Nasdaq: CELU) (\u201cCelularity\u201d or the \u201cCompany\u201d), a regenerative and cellular medicine company, today announced that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. With this filing, the Company is now current on its quarterly report filings. For the nine months ended September 30, 2024, Celularity reported total net &hellip; Continue reading &quot;Celularity Reports Over Sevenfold Growth in Net Product Sales\u00a0through Third Quarter 2024 Compared to Third Quarter 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-06T13:04:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTQxOSM2NjI2NDM0IzIyMDUwMDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Celularity Reports Over Sevenfold Growth in Net Product Sales\u00a0through Third Quarter 2024 Compared to Third Quarter 2023\",\"datePublished\":\"2024-12-06T13:04:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\\\/\"},\"wordCount\":967,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTQxOSM2NjI2NDM0IzIyMDUwMDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\\\/\",\"name\":\"Celularity Reports Over Sevenfold Growth in Net Product Sales\u00a0through Third Quarter 2024 Compared to Third Quarter 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTQxOSM2NjI2NDM0IzIyMDUwMDk=\",\"datePublished\":\"2024-12-06T13:04:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTQxOSM2NjI2NDM0IzIyMDUwMDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTQxOSM2NjI2NDM0IzIyMDUwMDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celularity Reports Over Sevenfold Growth in Net Product Sales\u00a0through Third Quarter 2024 Compared to Third Quarter 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celularity Reports Over Sevenfold Growth in Net Product Sales\u00a0through Third Quarter 2024 Compared to Third Quarter 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/","og_locale":"en_US","og_type":"article","og_title":"Celularity Reports Over Sevenfold Growth in Net Product Sales\u00a0through Third Quarter 2024 Compared to Third Quarter 2023 - Market Newsdesk","og_description":"Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024,\u00a0 and is now current with its quarterly report filings Reported Total Net Revenue for the Three Months and the Nine Months ending September 30, 2024, are consistent with last guidance, with significant growth over the same periods in 2023 FLORHAM PARK, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) &#8212; Celularity Inc. (Nasdaq: CELU) (\u201cCelularity\u201d or the \u201cCompany\u201d), a regenerative and cellular medicine company, today announced that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. With this filing, the Company is now current on its quarterly report filings. For the nine months ended September 30, 2024, Celularity reported total net &hellip; Continue reading \"Celularity Reports Over Sevenfold Growth in Net Product Sales\u00a0through Third Quarter 2024 Compared to Third Quarter 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-06T13:04:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTQxOSM2NjI2NDM0IzIyMDUwMDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Celularity Reports Over Sevenfold Growth in Net Product Sales\u00a0through Third Quarter 2024 Compared to Third Quarter 2023","datePublished":"2024-12-06T13:04:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/"},"wordCount":967,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTQxOSM2NjI2NDM0IzIyMDUwMDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/","name":"Celularity Reports Over Sevenfold Growth in Net Product Sales\u00a0through Third Quarter 2024 Compared to Third Quarter 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTQxOSM2NjI2NDM0IzIyMDUwMDk=","datePublished":"2024-12-06T13:04:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTQxOSM2NjI2NDM0IzIyMDUwMDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTQxOSM2NjI2NDM0IzIyMDUwMDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-reports-over-sevenfold-growth-in-net-product-sales-through-third-quarter-2024-compared-to-third-quarter-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Celularity Reports Over Sevenfold Growth in Net Product Sales\u00a0through Third Quarter 2024 Compared to Third Quarter 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=793050"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793050\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=793050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=793050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=793050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}